Lobeline shows protective effects against MPTP‑induced dopaminergic neuron death and attenuates behavior deficits in animals

Li,Chao‑Yue; Zhao,Li‑Ming; Shi,Xi‑Wen; Zhang,Jia‑Dong

doi:10.3892/etm.2013.1413

Lobeline shows protective effects against MPTP‑induced dopaminergic neuron death and attenuates behavior deficits in animals

Authors:
- Chao‑Yue Li
- Li‑Ming Zhao
- Xi‑Wen Shi
- Jia‑Dong Zhang
View Affiliations

Affiliations: Department of Neurosurgery, Henan Province People's Hospital, Zhengzhou, Henan 450003, P.R. China
Published online on: November 18, 2013 https://doi.org/10.3892/etm.2013.1413
Pages: 375-378

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously demonstrated that lobeline effectively inhibited dopamine transporter (DAT)‑mediated dopamine (DA) transportation. Therefore, the present study aimed to investigate whether lobeline shows protective effects against neurotoxin‑induced cell death in vivo. Mice were administered 30 mg/kg 1‑methyl‑4‑phenyl‑1,2,3,6‑tetra‑hydropyridine (MPTP) and treated with 80 mg/kg L‑dopa, 10 mg/kg GBR12935 or 1 or 3 mg/kg lobeline, respectively, via injection. Rotarod and swim tests as well as tyrosine hydroxylase (TH) immunohistochemistry were carried out to evaluate the effects of these drugs. Compared with L-DA and GBR12935, lobeline (3 mg/kg administered via intraperitoneal injection) on behavior and dopaminergic neurons. Compared with L-DA and GBR12935, lobeline (3 mg/kg injected subcutaneously) significantly reduced MPTP induced locomotive deficits detected in behavioral tests. In addition, TH immunostaining showed that lobeline (3 mg/kg) markedly decreased the neurotoxin‑induced immunoreactivity loss in the substantia nigra and striatum. Lobeline may be useful in the protection of dopaminergic neurons and may alleviate the symptoms of Parkinson's disease.

View Figures

View References

1	Agid Y: Parkinson’s disease: pathophysiology. Lancet. 337:1321–1324. 1991.
2	Ono S, Hirai K and Tokuda E: Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease. Biol Pharm Bull. 32:1813–1817. 2009. View Article : Google Scholar : PubMed/NCBI
3	Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V and Brotchie JM: Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol. 63:1343–1344. 2006. View Article : Google Scholar : PubMed/NCBI
4	Tayarani-Binazir K, Jackson MJ, Rose S, McCreary AC and Jenner P: The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Exp Neurol. 226:320–327. 2010. View Article : Google Scholar : PubMed/NCBI
5	Barlow RB and Johnson O: Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (−)-cytisine and (−)-lobeline hydrochloride and a comparison with (−)-nicotine and other nicotine-like compounds. Br J Pharmacol. 98:799–808. 1989.PubMed/NCBI
6	Dimatelis JJ, Russell VA, Stein DJ and Daniels WM: The effects of lobeline and naltrexone on methamphetamine-induced place preference and striatal dopamine and serotonin levels in adolescent rats with a history of maternal separation. Metab Brain Dis. 27:351–361. 2012. View Article : Google Scholar
7	Rozas G and Labandeira García JL: Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res. 749:188–199. 1997. View Article : Google Scholar : PubMed/NCBI
8	Damier P, Hirsch EC, Agid Y and Graybiel AM: The substantia nigra of the human brain. I Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 122:1421–1436. 1999. View Article : Google Scholar
9	Szego ÉM, Gerhardt E, Kermer P and Schulz JB: A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice. Neurobiol Dis. 45:591–600. 2012.
10	Graham D and Langer SZ: Advances in sodium-ion coupled biogenic amine transporters. Life Sci. 51:631–645. 1992. View Article : Google Scholar : PubMed/NCBI
11	McChargue DE, Collins FL Jr and Cohen LM: Effect of non-nicotinic moist snuff replacement and lobeline on withdrawal symptoms during 48-h smokeless tobacco deprivation. Nicotine Tob Res. 4:195–200. 2002. View Article : Google Scholar : PubMed/NCBI
12	Liu R, Guo X, Park Y, Huang X, Sinha R, Freedman ND, Hollenbeck AR, Blair A and Chen H: Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol. 175:1200–1207. 2012. View Article : Google Scholar : PubMed/NCBI
13	Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A and Blair A: Smoking duration, intensity, and risk of Parkinson disease. Neurology. 74:878–884. 2010. View Article : Google Scholar : PubMed/NCBI
14	Sieber M: Neuroprotective properties of nicotine. Curr Med Chem. 19:292–297. 2012. View Article : Google Scholar
15	Singh K, Singh S, Singhal NK, Sharma A, Parmar D and Singh MP: Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism. Chem Biol Interact. 185:81–93. 2010. View Article : Google Scholar
16	Li Y, Yu DQ, Peng Y, Feng YH, Zhang DM, Zhao J, Zhang WQ and Sun YP: The protective effect of nicotine on dopaminergic neuron of Parkinson’s disease mice. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 23:425–429. 2007.(In Chinese).
17	Parain K, Hapdey C, Rousselet E, Marchand V, Dumery B and Hirsch EC: Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res. 984:224–232. 2003. View Article : Google Scholar
18	Harrod SB, Lacy RT, Zhu J, Hughes BA, Perna MK and Brown RW: Gestational IV nicotine produces elevated brain-derived neurotrophic factor in the mesocorticolimbic dopamine system of adolescent rat offspring. Synapse. 65:1382–1392. 2011. View Article : Google Scholar
19	Toulorge D, Guerreiro S, Hild A, Maskos U, Hirsch EC and Michel PP: Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2⁺. FASEB J. 25:2563–2573. 2011. View Article : Google Scholar : PubMed/NCBI